Work

Pharmacologic and Genetic Investigation of PI3K p110delta in Chronic Lymphocytic Leukemia

Year: 2017
Type: article
Abstract: Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the western world.The treatment strategies of CLL have undergone a paradigm shift in the last decade.Without a disease defining gene abnormality, the Achilleas heels of CLL is its microenvironment dependency.Upon discovering the importance of CLLmicroenvironment cross-talk and essential survival B cell receptor (BCR) pathways, small molecule inhibitors that target BCR pathways were soon developed and showed profound activity in preclinical and clinical studies.Several agents that target BCR pathways also reverse tumor related immune suppression.Idelalisib is one such therapy directed at phosphoinositide 3-kinase isoform δ, an essential component of BCR signaling in normal and transformed B-cells and essential for the activation of regulatory T cells.CLL is dependent upon BCR signaling and mediates profound immune suppression and tumor tolerance.Idelalisib is a PI3K p110δ inhibitor with significant clinical benefit and also toxicities resembling autoimmunity.Using a PI3K p110δ and p110γ inhibitor IPI-145, we show that PI3K p110δ/p110γ blockade in leukemia cells overcomes microenvironmental BCR-and CD40L-stimulation, antagonizes pro-survival AKT pathway and induces selective cytotoxicity to leukemia cells.PI3K p110δ/p110γ blockade reduces TCR-induced T cell proliferation and cytokine production, suggesting PI3K p110δ/p110γ have dual roles in the leukemic and normal iii immune compartment.PI3K p110δ/p110γ inhibition does not impair natural killer cellmediated cellular cytotoxicity.Most importantly, PI3K p110δ/p110γ inhibition can overcome ibrutinib resistance due to the BTK C481S mutation.Using different genetic mouse models, we demonstrate that global inactivation of p110δ blocks leukemia development, confirming that p110δ is critical for CLL initiation and progression.Additionally, blocking p110δ activity in the microenvironment protects against both murine CLL and acute myeloid leukemia due to the lack of regulatory T cell immunosuppression.These data suggest a separate immunomodulatory effect of p110δ blockade independent of BCR signaling or direct tumor efficacy.Collectively, these data suggest p110δ blockade may have a broader immune modulatory role across other types of leukemia.iv Dedication Dedicated to my family,
Author: Dong, Shuai
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: green
OpenAlex ID: W7042556334
FWCI: 0.18
Cites: 103
Cited by: 1
Related to: 10